Asano Yoshihide, Ihn Hironobu, Jinnin Masatoshi, Tamaki Zenshiro, Tamaki Kunihiko, Sato Shinichi
Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
J Dermatol. 2014 Aug;41(8):746-8. doi: 10.1111/1346-8138.12563. Epub 2014 Jul 16.
Matrix metalloproteinase-13 (MMP-13), a member of the collagenase family, has been implicated in the pathogenesis of connective tissue diseases characterized by extracellular matrix remodeling. Since serum MMP-13 levels reflect disease severity of systemic sclerosis and localized scleroderma, we evaluated the clinical significance of serum MMP-13 levels in eosinophilic fasciitis (EF). All the EF patients had serum MMP-13 levels lower than the mean - 2SD of healthy controls. Serum MMP-13 levels were also significantly decreased in EF patients compared with diffuse cutaneous systemic sclerosis, limited cutaneous systemic sclerosis, and generalized morphea patients. Although serum MMP-13 levels did not reflect any clinical and serological features of EF, these results indicate that MMP-13 may be involved in the development of this disease.
基质金属蛋白酶-13（MMP-13）是胶原酶家族的一员，与以细胞外基质重塑为特征的结缔组织疾病的发病机制有关。由于血清MMP-13水平反映系统性硬化症和局限性硬皮病的疾病严重程度，我们评估了血清MMP-13水平在嗜酸性筋膜炎（EF）中的临床意义。所有EF患者的血清MMP-13水平均低于健康对照的平均值减2个标准差。与弥漫性皮肤系统性硬化症、局限性皮肤系统性硬化症和泛发性硬斑病患者相比，EF患者的血清MMP-13水平也显著降低。虽然血清MMP-13水平未反映EF的任何临床和血清学特征，但这些结果表明MMP-13可能参与了该疾病的发生发展。
